Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial [PDF]
, 2017 BACKGROUND/OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to ...
Boustani, Malaz A. +8 more
core +1 more source
Can we predict the response to Galantamine in Alzheimer`s disease patients? [PDF]
Romanian Journal of Neurology, 2015 Although considerate progress was obtained by adding imagistic and laboratory test, clinical examination remains the core of the diagnosis for Alzheimer`s disease. After 20 years of experience with anticholinergic drugs we know that only one third of the
Carmen Gavan +2 more
doaj +1 more source
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]
, 2015 This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Abagyan, Ruben +4 more
core +3 more sources
Galantamine Effects on Memory, Spatial Cue Utilization, and Neurotrophic Factors in Aged Female Rats
Cell Transplantation, 2007 Galantamine is an acetylcholine esterase inhibitor that has been approved for use in Alzheimer's disease. However, even though clinical studies indicate efficacy in attenuating some of the symptoms associated with the disease, there are a paucity of ...
K. L. French +2 more
doaj +1 more source
Biological activities and chemical composition of methanolic extracts of selected Autochthonous microalgae strains from the Red Sea [PDF]
, 2015 Four lipid-rich microalgal species from the Red Sea belonging to three different genera (Nannochloris, Picochlorum and Desmochloris), previously isolated as novel biodiesel feedstocks, were bioprospected for high-value, bioactive molecules.
Carolina Bruno De Sousa +14 more
core +4 more sources
Potential therapeutic use of the ketogenic diet in autism spectrum disorders. [PDF]
, 2014 The ketogenic diet (KGD) has been recognized as an effective treatment for individuals with glucose transporter 1 (GLUT1) and pyruvate dehydrogenase (PDH) deficiencies as well as with epilepsy.
Dueñas, Nadia +2 more
core +1 more source
Journal of Pharmacological Sciences, 2006 .: The cholinergic system undergoes changes with aging and in Alzheimer’s disease. The effects of the anticholinesterase drugs galantamine and donepezil were studied in a model with sodium nitrite-induced hypoxia in rats.
Dimitrova Darinka Slavcheva +1 more
doaj +1 more source
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis [PDF]
, 2003 Background Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their
Jaime Caro +5 more
core +2 more sources
Het effect van galantamine op de ecg- geleidingstijden
Tijdschrift voor Gerontologie en Geriatrie, 2014 Achtergrond Galantamine, een acethylcholinesterase-remmer (AChE-remmer), is geregistreerd voor de symptomatische behandeling van lichte tot matig ernstige dementie van het Alzheimer-type.
I. C. Jobse, R. A. M. de Jonckheere
doaj +1 more source
Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2020 Introduction Gln‐1062 (MEMOGAIN) is an intranasally administered lipophilic prodrug of galantamine. Based on high brain‐to‐blood concentrations observed in pre‐clinical studies, Gln‐1062 is expected to have superior cognitive efficacy compared to oral ...
Charlotte Bakker +7 more
doaj +1 more source